OncoMatch/Clinical Trials/NCT06710756
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Is NCT06710756 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 for pancreatic ductal adenocarcinoma.
Treatment: [203Pb]Pb-PSV359 · [212Pb]Pb-PSV359 — Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Gastric Cancer
Esophageal Carcinoma
Colorectal Cancer
Ovarian Cancer
Head and Neck Squamous Cell Carcinoma
Sarcoma
Mesothelioma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic anticancer therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Saint Louis University · St Louis, Missouri
- Nebraska Cancer Specialists · Omaha, Nebraska
- University of Pittsburgh Medical Center · Pittsburgh, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06710756 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 90 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages